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Abstract. Multidrug-resistant tuberculosis (MDRTB) rates in a human immunodeficiency virus (HIV) care facility
increased by the year 2000—56% of TB cases, eight times the national MDRTB rate. We reported the effect of tuberculosis
infection control measures that were introduced in 2001 and that consisted of 1) building a respiratory isolation ward
with mechanical ventilation, 2) triage segregation of patients, 3) relocation of waiting room to outdoors, 4) rapid sputum
smear microscopy, and 5) culture/drug–susceptibility testing with the microscopic-observation drug-susceptibility assay.
Records pertaining to patients attending the study site between 1997 and 2004 were reviewed. Six hundred and fifty five
HIV/TB–coinfected patients (mean age 33 years, 79% male) who attended the service during the study period were
included. After the intervention, MDRTB rates declined to 20% of TB cases by the year 2004 (P = 0.01). Extremely
limited access to antiretroviral therapy and specific MDRTB therapy did not change during this period, and concurrently,
national MDRTB prevalence increased, implying that the infection control measures caused the fall in MDRTB rates.
The infection control measures were estimated to have cost US$91,031 while preventing 97 MDRTB cases, potentially
saving US$1,430,026. Thus, this intervention significantly reduced MDRTB within an HIV care facility in this resource-
constrained setting and should be cost-effective.
INTRODUCTION
The emergence of multidrug-resistant tuberculosis (MDRTB)
and its interaction with human immunodeficiency virus (HIV)
infection have complicated global efforts to control tuberculo-
sis (TB).1,2 TB accelerates viral replication and progression to
acquired immunodeficiency syndrome in HIV-infected patients,
whereas HIV infection speeds progression to active TB after
both long-standing latent and recently acquired infection.3–5
The superposition of the HIV and TB epidemics has led to
high TB rates and TB outbreaks within HIV care facilities in
cities including Madrid, Miami, and New York.5–8 In resource-
constrained and wealthier countries alike, most of these out-
breaks have involved MDRTB.6,9–12 In Latin America, high
TB and MDRTB rates in association with HIV coinfection
have been reported in Argentina11,13 and Peru. In Peru, a
survey of patients receiving care at 10 large hospitals across
Lima and Callao reported that 43% of patients with HIV/TB
coinfection had MDRTB, compared with 3.9% of TB patients
who were HIV negative.14
Strategies to combat nosocomial TB transmission have
generally prioritized reducing the number of patient sources
of infection, and infection control measures to limit the prop-
agation of airborne TB within the hospital. These measures
include a greater index of suspicion for TB, improving labora-
tory methods for TB diagnosis and drug-susceptibility testing,
optimizing drug regimens to ensure effective treatment of
individual cases, and isolation of infected patients.9,15,16
Employing such measures during nosocomial outbreaks has
led to better management of outbreaks and has limited fur-
ther transmission.9,12
In Peru, TB control measures during the 1990s centered
on improving directly observed treatment, short-course
(DOTS) for TB patients diagnosed by sputum smear micros-
copy, and in some settings, additionally the provision of
isoniazid prophylaxis for HIV-positive patients without evi-
dence of active TB. However, in some global settings, the
impact of DOTS on TB and MDRTB control has been
undermined by ineffective infection control programs, weak
health systems infrastructure, and a lack of availability of
second-line anti-TB drugs for HIV-positive patients.17
Analysis of Mycobacterium tuberculosis strains from
patients with and without HIV coinfection at the Hospital
Dos de Mayo (HDM) in Lima using restriction fragment
length polymorphism identified “cluster” cases, suggesting
transmission within this group of patients.18 Moreover, resis-
tance rates were found to be increasing rapidly: in 1994–1995,
20% of evaluated patients had resistance to one or more
drugs and 4% had MDRTB, rising to 71% resistance to one
or more drugs including 41% MDR by 1997–1998.19–21
Despite evidence of ongoing nosocomial transmission of
MDRTB in this hospital for several years,22 this was not incor-
porated in national TB reports for the year 2000.23,24 How-
ever, as a result of this evidence of nosocomial MDRTB
transmission, the HDM administration authorized a team from
the Infectious and Tropical Diseases department of HDM,
with individual and institutional volunteers, to implement
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enhanced infection control measures. Herein, we describe
these measures, their costs, and MDRTB rates before and
after these measures were introduced.
METHODS
Study design and ethics. This study retrospectively assessed
programmatically recorded data at the adult HIV care facility
at the Dos De Mayo public tertiary referral hospital, Lima,
Peru, from 1997 to 2004. Annually, this facility had an average
of 310,948 outpatient visits and 360 hospitalizations of people
at least 18 years of age, during this period. We examined
records from all patients ≥ 18 years of age who were HIV
positive and TB coinfected. Only patients with culture-positive
samples were included in this study, to be able to classify
patients according to culture-based drug susceptibility. HIV
infection was defined by at least two positive HIV antibody
test results: one in the hospital’s onsite laboratory, and a con-
firmatory test performed in the Peruvian National Institutes
of Health (NIH) reference laboratory. We aimed to compare
these data before versus after infection control measures that
were introduced to address a clinical need and to improve the
standard of care, not for research purposes. The internation-
ally accredited ethics committee at the nongovernmental orga-
nization Asociacion Benéfica Proyectos en Informatica, Salud,
Medicina, y Agricultura (PRISMA), Lima, Peru, considered that
as no human subject research was performed, retrospective anal-
ysis of these anonymous data did not require ethical approval.
Data collection. This study did not affect patients’ routine
clinical care that involved their nurses and/or doctors entering
personal data into books. These data included sex, age, date(s)
of outpatient attendance and/or admission to and discharge from
the ward, date of HIVand/or TB diagnosis, and results of sputum
smear microscopy, culture and susceptibility testing for first-line
TB drugs. These data were digitized for the current research.
Infection control measures. The infection control measures
were developed according to international recommendations25
and constituted 1) building a respiratory isolation ward with
mechanical ventilation, 2) triage segregation of patients,
3) relocation of the outpatient waiting area from within to
outside the building, 4) rapid sputum smear microscopy, and
5) culture with integrated drug-susceptibility testing with the
Microscopic Observation Drug Susceptibility (MODS) assay.
These components of the intervention are described below.
The respiratory isolation ward. The original HIV ward
consisted of a single room measuring 35 × 8 × 4.5 m with
10 large windows that permitted a transverse flow of air pro-
viding high levels of natural ventilation.26 Enabled by dona-
tions, in 2000–2001, an adjacent unused building was converted
into an isolation ward to which patients with suspected or
proven TB were admitted instead of the original ward since
2001. The construction work transiently reduced the number
of patients who could be admitted to the ward in 2001. The
isolation ward initially consisted of three six-bedded rooms
plus one single-patient room. After 4 months, the number of
patients was reduced to four per room. In 2002, each four-
bedded room was divided into a cluster of four individual
rooms, each with a shared bathroom (Figure 1). The third
room continued to be shared by up to four patients. Patients
with confirmed or suspected MDRTB were accommodated in
one cluster of four individual rooms (Figure 1). The isolation
ward incorporated a mechanical ventilation system, and all
rooms had negative pressure and 6–8 changes/hour as
recommended at that time.27,28 In addition, the waiting area
for outpatients, although considered adequately ventilated,
was relocated to the gardens adjacent to the outpatient clinic
rooms, allowing greater distance between each patient and
greater dilution of respiratory droplets.
Triage segregation of patients and waiting area relocation. From
2001 on, all patients with negative sputum smear microscopy
were hospitalized in the original open ward, and all patients
with positive sputum smear microscopy were isolated in the
respiratory isolation ward. However, it was noted that in some
patients who had been smear negative on admission, there was
ongoing clinical suspicion of TB and subsequent positive smear
microscopy results. Consequently, in 2002, the admission pro-
tocol was modified (Figure 2) so that all patients with cough
suspected to be caused by TB were isolated in side rooms
until TB was felt by the responsible clinician to have been
confidently excluded on the basis of sequential sputum smear
microscopy results, clinical assessment, and radiological eval-
uation. The MODS assay or epidemiological criteria were
used to identify suspected MDRTB patients. These epidemio-
logical criteria were failure to respond adequately to first-line
treatment; contact with patients known to have MDRTB;
early relapse after completion of first-line treatment; and
multiple hospitalizations.
Rapid sputum smear microscopy and MODS. In 2001,
mandatory sputum smear microscopy at the time of outpatient
review and/or hospitalization was established for all patients
with respiratory symptoms. To facilitate this, rapid sputum
smear microscopy was made available 12 hours/day, 6 days/
week at the hospital laboratory. Forty percent of the patients
had access to MODS assays, which permitted enhanced diag-
nosis in sputum smear-negative patients, and facilitated earlier
isolation of patients with MDRTB.
Other practices that were unaffected by the infection control
measures included natural ventilation by keeping windows
open 24 hours a day and the obligatory use of highly protec-
tive N95 respirators by all health-care workers in contact with
HIV-positive patients with suspected or proven pulmonary TB.
These respirators have been available in Peru since 1997, and
have been in widespread use since 1999.
TB culture and drug-susceptibility testing. Information
about the availability of drug-susceptibility testing and first-
and second-line drugs, for HDM patients and for all patients
across Lima, are presented in Table 1. These data were
obtained from the Ministry of Health, Lima, Peru (MINSA),
and from records maintained at HDM.
TB culture was performed on solid Ogawa medium in
the hospital laboratory as per standard practice. Positive iso-
lates were sent to the Peruvian NIH laboratory for drug-
susceptibility testing. Susceptibility testing for first-line TB
drugs using the proportions method was available through-
out the study period. In Lima, limited testing for susceptibility
to second-line TB drugs became available from 1999 through
the laboratory of the organization Partners in Health (PIH).
These samples were sent to the Massachusetts State Labora-
tory Institute where testing was performed using the propor-
tion method on 7H10 agar plates and, for pyrazinamide, the
BACTEC method,29,30 and as a result, a significant turn-
around time of several weeks could be expected. Moreover,
testing was not available for patients attending sites (including
HDM) that were geographically outside the PIH center’s
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catchment area, which was restricted to north Lima. Suscepti-
bility testing for second-line drugs became universally avail-
able through the Peruvian NIH laboratory in 2005, which was
after the study period had ended.
For some patients attending HDM, MODS assay31,32 was
performed at the Universidad Peruana Cayetano Heredia’s
laboratory. Its use during this study period was for research
purposes only, as MODS was undergoing development and
validation at that time, and the results were not recognized
by the Peruvian NIH laboratory or Ministry of Health until
2005. As second-line drugs were approved and provided by
the NIH, the results of the MODS assay were not used to
inform treatment decisions. They were used to guide local
infection control measures, however, as they were available
to clinicians much more rapidly (usually 1–3 weeks) than
those of the Peruvian NIH laboratory.
Molecular testing was not performed as part of this study.
However, some of the participants included in this retro-
spective analysis gave informed written consent to provide
sputum samples for a study of TB diagnostics and drug sus-
ceptibility that had prior ethical approval, the results of
which are reported in an accompanying article in publica-
tion process.
Data analysis. For the purposes of analysis, a case of TB
was defined as an individual who had a TB diagnosis con-
firmed by a positive M. tuberculosis culture and for whom
phenotypic drug-susceptibility data were available. To assess
the impact of TB infection control measures during fluctua-
tions in ward occupancy and capacity, the percentage of
patients with TB who had MDRTB before and after the inter-
vention were compared using the unpaired Student’s t test
and the z-test of proportions.
These data were interpreted with reference to published
national prevalence survey data defining the percentage of
MDRTB among new and retreated patients.
Cost analysis. The number of MDRTB cases that the inter-
vention prevented was estimated by calculating the propor-
tion of MDRTB cases among total TB cases before, during,
FIGURE 1. (A) Initial floorplan of the human immunodeficiency virus (HIV) service before the intervention. (B) Final layout of the respiratory
isolation area at the HIV service, from 2002 to the present day.
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and after the intervention. The potential economic impact
of the intervention was estimated by comparing potential
savings from reducing the number of patients treated for
MDRTB with the cost of the intervention. The cost of the
intervention was calculated to include costs of new infrastruc-
ture and equipment plus annual maintenance. The potential
cost of standardized second-line treatment of 18 months was
calculated using costs previously reported,29,33 which include
drugs, laboratory tests, and personnel.
RESULTS
A total of 912 patients with HIV/TB coinfection who had
attended the HIV care facility during the study period were
identified. Of these patients, 257 were excluded from analysis
because of an absence of positive HIV test confirmation and/
or because it was not possible to classify the patient as having
drug-sensitive versus drug-resistant TB. Thus, 655 patients
were included in the study. The mean age was 33 years, and
79% were male. No patients were taking sustained antiretro-
viral therapy (ART).
In 1997, 44% (52/117) HIV/TB–coinfected patients were
diagnosed with MDRTB (Table 2). This percentage increased
to peak at 56% (45/80 patients) in 2000, the year before the
infection control measures took effect, and subsequently
decreased to reach 20% (18/91 patients) in the year 2004.
The trends in MDRTB rates among HIV/TB–coinfected
patients are presented in Table 2 and illustrated in Figure 3.
For the 4 years before the infection control measures (1997–
2000) combined, 48% of patients with TB had MDRTB
(179/376), which was significantly higher (P < 0.0001) than
for the 3 years after the infection control measures (2002–
2004) when the MDRTB rate fell to 27% (65/244). Similarly,
the number of MDRTB cases reduced significantly after the
infection control measures were introduced (P < 0.0001).
During the study, national Peruvian prevalence surveys
of randomly selected previously treated and untreated TB
patients showed that in both of these groups, the MDRTB
rates were increasing (Figure 3).34,35 Complete data were not
recorded concerning MDRTB treatment at HDM during the
period of this study. Two published studies, however, provide
partial data. The first study recruited 30 patients with
MDRTB from February 1999 to July 2000, 12 of whom had
any access to second-line drugs.36 The second study recruited
50 patients at HDM with MDRTB between 2002 and 2003,
only 15 of whom received any second-line drugs.18
The infection control measures prevented an estimated
97 cases of MDRTB in HIV-positive patients who received
treatment from 2001 to 2004. The results of the economic
analysis are given in Table 3. The infection control interven-
tion was estimated to have caused an overall potential saving
of US$1,430,026 if these cases had not been prevented and
had instead been treated with second-line therapy.
DISCUSSION
This study shows that infection control measures designed
to prevent TB transmission had a significant impact controlling
an outbreak of MDRTB among HIV-positive patients in a
tertiary referral hospital in Lima, Peru. In line with the lack
FIGURE 2. Triage flow diagram of admission procedures for the respiratory isolation area.
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of resources available in resource-constrained countries for such
structural changes, these measures were developed with limited
funding and introduced stepwise rather than simultaneously.
Table 1 indicates that the time period analyzed for this
study was crucial in the fight against TB transmission at
HDM and also across Lima as a whole. Very few patients
with MDRTB were receiving appropriate treatment of their
disease. At the onset of the study, both drug-susceptibility
testing and provision of second-line drugs were scarce, only
becoming universal right at the end of this time. Where they
were available, the treatment regimens in use for MDRTB at
that time were mostly standardized regimens, rather than
individualized regimens that take into consideration an indi-
vidual patient’s drug-susceptibility data. Moreover, the avail-
ability of susceptibility testing and second-line treatment to
HIV-positive patients, the subjects of this study, remained
low throughout the study period. The appearance and rise in
frequency of XDRTB is important and may reflect sub-
optimal management of TB patients. It is likely, therefore,
that the changes in intervention control management
implemented within the service made a significant contribu-
tion to the reduction in the proportion of MDRTB patients
seen in our HIV/TB–coinfected population.
The striking and statisitically significant decrease in the
proportion of MDRTB among HIV-positive patients with
TB seen in this study is consistent with reports from Hospital
Muñiz in Buenos Aires, Argentina, where the proportion of
MDRTB cases among HIV-coinfected patients reduced from
16% in 1995 to 7% in 2001.37 In both hospitals, infection
control measures included measures to improve detection of
TB before and during admission, and isolation of patients
with MDRTB.6 However, some methodological differences
exist between the two studies. For example, in Hospital
Muñiz, detection of drug resistance was performed using
FIGURE 3. Trends in the rate of multidrug-resistant tuberculosis (MDRTB) among human immunodeficiency virus (HIV)/tuberculosis (TB)–
coinfected patients before and after the implementation of the infection control intervention, HNDM = Hospital Nacional Dos de Mayo.
TABLE 2
Annual numbers of patients with HIV/TB coinfection seen at the HIV service, and rates of MDRTB among these patients
Year
Preintervention Construction Intervention
1997 1998 1999 2000 2001 2002 2003 2004
Patients with HIV/TB coinfection 117 99 80 80 35 65 88 91
(all cases, drug-susceptible and MDRTB)
Patients with HIV/TB coinfection, non-MDRTB 65 57 40 35 18 44 62 73
Patients with HIV/MDRTB coinfection 52 42 40 45 17 21 26 18
% of total HIV/TB coinfection 44 42 50 56 49 32 30 20
Average (%) of total
HIV/TB coinfection
48 49 27
Ratio, MDR:non-MDR case 0.80 0.74 1.00 1.29 0.94 0.48 0.42 0.25
Average ratio, MDR:non-MDR case 0.91 0.94 0.36
Predicted no. of MDRTB cases if the intervention
had not occurred and the baseline MDRTB rate had continued
NA NA NA NA NA 40 56 66
Estimated no. of MDRTB cases prevented by
the intervention
NA NA NA NA NA 19 30 48
HIV = human immunodeficiency virus; MDR = multi-drug resistant; NA = not applicable; TB = tuberculosis.
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relatively rapid radiometric methods, and second-line TB
medications were available for patients who required them.
In contrast, our HIV service relied mainly on the proportions
method for drug-susceptibility testing, so results were not avail-
able for several weeks or months. In addition, HIV-positive
patients had severely limited access to second-line drugs as
shown in Table 1 and described above. Furthermore, when
second-line drugs were available, significant delays in obtaining
and initiating these were almost universal, as reported previ-
ously.29 A small number of patients are known to have pur-
chased second-line drugs privately36; however, these drug
supplies were limited, were not prescribed according to
recommended regimens, were often available only intermit-
tently, and the duration for which they were taken is not
known. This treatment was therefore inadequate. For these
reasons, the occasional use of second-line drugs among our
patients has not been included in this analysis.
Although nosocomial transmission of TB is believed to
have been a long-standing problem in this HIV service, the
outbreak of MDRTB documented by this report drew atten-
tion to this issue and prompted the introduction of rigorous
infection control measures in the hospital as described. This
infection control strategy reflected infection control policy
recommendations from both the Centers for Disease Control
and Prevention and World Health Organization, and there-
fore, our findings support those recommendations.25,38 In a
study of 600 Peruvian TB patients over a 5-year period, 8.1%
of patients with non-MDRTB were found to have acquired
MDRTB during DOTS. This was 2.8 times more likely among
HIV-positive patients (P = 0.001). In addition, acquiredMDRTB
was 34 times more likely to occur in clinics with higher pro-
portions of patients with suspected MDRTB, suggesting trans-
mission within these clinics.39
Among environmental control measures used in develop-
ing countries, natural ventilation is popular because it is con-
sidered to be effective and is less expensive than mechanical
ventilation.40,41 The natural variation in airflow patterns dur-
ing the day caused by local climate and other factors, the
closing of windows at night, or the presence of highly infec-
tious patients mean that its effectiveness can be highly vari-
able, and complete elimination of infectious particles from
the environment is not possible.26,41 However, isolation
rooms equipped with negative pressure and mechanical ven-
tilation typically guarantee an adequate and stable exchange
of air, provided they are correctly designed and installed
and well maintained. This ensures that contaminated air is
channelled into a safe area alnd does not escape to other
public places such as another ward, reception room, or
doctor’s office.42
This nosocomial outbreak of MDRTB occurred in an envi-
ronment that was already equipped with natural ventilation
facilitated by high ceilings and large windows. Additionally,
infection control policies at the time advocated windows to be
open 24 hours a day. However, in spite of the cross-ventilation,
this policy was not followed due to various inevitable circum-
stances where patients needed the windows closed, such as
cold weather, security, or sometimes when the privacy of the
patients was compromised. It is clear that HIV-positive
patients are highly susceptible to infection with TB,43–45 and
our data further suggest that in this HIV ward for patients
coinfected with TB, natural ventilation appeared to be insuf-
ficient to prevent transmission of TB. This evidence suggests
that it may be necessary to use such additional measures in
this type of setting.
The TB isolation ward was designed to provide six air
changes per hour, consistent with recommendations at that
time; however, since then, recommendations have increased
to 12 changes/hour.27,28,46 This study demonstrates that in
settings where achieving 12 air changes/hour is beyond
resource availability, patient triage and segregation of infec-
tious patients into rooms with lower levels of mechanical
ventilation may considerably reduce MDRTB transmission.
Although the costs of the implementation and maintenance
of the infection control measures described are significant, the
reduction in the number of cases of MDRTB observed in this
study produced a significant potential saving if second-line
drugs had been available, estimated at US$1,430,026 during
the study period. It is likely that the real savings are in fact
much higher when the burden of MDRTB on quality of life33
and the economic costs to the family and society47 are consid-
ered. In addition, there are cost savings through a reduction
in transmission of MDRTB in the community. This is espe-
cially important among the HIV-positive population given
their greater susceptibility to TB infection as well as the
higher rates of TB disease in HIV patients.
A limitation of this cost-effective model arises from the
nature of TB infection in HIV-positive patients. The rapidly
fatal nature of TB/HIV coinfection means that some patients
may have succumbed to the disease before treatment with
second-line drugs could be completed, or even initiated, thus
reducing the expected expenditure on medications. This
would depend upon the speed of detection of drug resistance
and ease with which second-line drugs could be approved
and obtained. Both of these factors were significant barriers
to provision of timely care in Lima at this time as discussed
above, and their effects are difficult to estimate. Moreover,
this is likely to have been offset in part by the increased bac-
terial burden and aerosolization generated by a small number
of individual “super spreaders” who are responsible for a sig-
nificant proportion of transmission in hospital settings.48
Particularly in developing countries, the combination of
natural and mechanical ventilation in care facilities, provision
of rapid sputum smear microscopy or other rapid diagnostic
tests such as MODS or the Xpert MTB/RIF assay (Cepheid,
USA), and patient isolation appears to be a useful and cost-
effective strategy to limit nosocomial transmission of TB
within HIV wards. It is not possible to quantify the relative
contribution of the separate components of the intervention
TABLE 3
Cost-effectiveness analysis of the implementation of the respiratory
isolation ward
Cost per unit (USD) Unit Total cost (USD)
57 MDRTB treatment29,33 15,681 97* 1,521,057
Implementation of
environmental
control measures
First building 57,887 1 57,887
Final building after 1 year 25,000 1 25,000
Maintenance cost 2,036 4† 8,144
Total cost 91,031
Overall savings 1,430,026
MDRTB = multi-drug resistant tuberculosis; USD = U.S. dollar.
*Number of cases averted during the study period.
†Duration of the study period in years.
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on the reduction in transmission, as the intervention was
implemented as an integrated package. In settings such as
this where both TB and HIV are endemic and patient num-
bers are large, it may not be possible to isolate all patients
with HIV, and thus the use of an algorithm to facilitate isola-
tion of patients coinfected with TB or suspected TB
(Figure 2) would represent a rational use of resources. This
policy could be particularly useful in settings where MDRTB
and/or extensively drug-resistant TB (XDRTB) are common.
The retrospective nature of this study and ethical consider-
ations preclude the use of a concurrent control group to
enable more rigorous evaluation of the infection control
measures. Although the possibility that the temporal changes
observed may have been due to other factors affecting TB
transmission during the study period cannot be excluded, the
marked reduction in numbers of patients diagnosed with
MDRTB after the intervention suggests that the change was
likely to be due to the infection control measures. Moreover,
the patients admitted to the ward did not receive ART and
very few received second-line drugs for TB, and the national
MDRTB rates changed little during the study; implying these
factors cannot therefore explain the rapid reduction in
MDRTB rates that were seen.
A separate study was conducted from 2002 to 2004 evalu-
ating upper-room ultraviolet light (UV) to prevent the trans-
mission of TB.49 During this period, the isolation rooms had
upper-room UV germicidal lights as part of the study. This
may also have contributed to our findings; again, it is not
possible to quantify the magnitude of its effect, particularly
given that it was not consistently used during the interven-
tion period.
In conclusion, this study has demonstrated that the imple-
mentation of a comprehensive TB control strategy including
a natural and mechanical ventilation and other measures was
associated with a marked reduction in nosocomial transmis-
sion of MDRTB in an HIV ward (Figure 4). We also showed
that these infection control measures were sustainable for
several years in this resource-constrained setting. This is con-
trary to commonly held beliefs that respiratory isolation is
almost impossible in such settings due to cost limitations,
whereas in fact, the cost-effectiveness analysis indicates that
this strategy has the potential to lead to considerable savings
that may justify the initial economic investment.
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